Harvard's 'reverse aging' research: what the epigenetic reprogramming studies actually show
A well-known Harvard aging researcher has spent years building evidence that aging might be more like a computer losing its settings than a car rusting — and that you could, in principle, restore the settings. It's worked repeatedly in mice, including reversing vision loss. In early 2026 it became the first such therapy allowed into a human trial — for an eye disease, not aging itself, and only to check safety so far. It's real, credible research — not yet a treatment anyone can use.
David Sinclair's Harvard lab has spent five years building a case that aging is, at its core, a loss of epigenetic information — not irreversible damage — and that restoring it can reverse aging markers. Two mouse studies back this up directly: one restored vision in mice with glaucoma and optic nerve injury, another showed that induced epigenetic 'noise' causally accelerates aging and that reprogramming reverses it. In January 2026, the FDA cleared the first human trial of this approach — a company Sinclair co-founded, Life Biosciences, is now testing a partial-reprogramming gene therapy (ER-100) in patients with glaucoma and NAION, two causes of vision loss. That trial is a safety-focused Phase 1 study, not proof the therapy works in humans — this is genuinely new territory, not an available treatment.
- The 'information theory of aging' proposes aging is caused by a progressive loss of epigenetic information (which genes are switched on or off) rather than accumulated damage to DNA itself — and that this loss is, in principle, reversible.
- Lu et al. 2020 (Nature) showed that expressing three reprogramming genes (Oct4, Sox2, Klf4 — OSK) in mouse retinal cells restored youthful DNA methylation patterns, regrew damaged optic-nerve axons, and reversed vision loss in mice with glaucoma and in aged mice.
- Yang et al. 2023 (Cell) went further: using a system that induces epigenetic 'noise' without damaging the DNA sequence itself, they showed this noise alone causally drives aging in mice at the physiological, cognitive, and molecular level — and that OSK reprogramming reverses it.
- In January 2026, the FDA cleared an Investigational New Drug application for ER-100, making it the first partial-reprogramming therapy ever authorized for human testing — a Phase 1 safety trial in patients with glaucoma and NAION, expected to enroll through 2026.
- No human efficacy data exists yet. This is the first human trial of the concept, not a validated therapy — treat any current marketing built on this research as riding on mouse data plus a safety trial in progress.
The idea: aging as lost information, not just damage
Every cell in your body has the same DNA, but a skin cell behaves differently from a neuron because of the epigenome — chemical tags on DNA and the proteins that package it, which control which genes are switched on. Sinclair's Information Theory of Aging (ITOA) argues that over a lifetime, this epigenetic "readout" becomes noisy: cells gradually lose their assigned identity and function, not because the underlying genetic code (the DNA sequence itself) is destroyed, but because the instructions for reading it degrade.
The useful part of this framing is that it makes a testable, falsifiable prediction: if aging is a loss of retrievable information rather than irreversible damage, then restoring the correct epigenetic pattern in an aged or damaged cell should make it behave younger again. That's exactly what the lab's two key mouse papers set out to test.
The mouse evidence: two separate studies, two separate proofs
The two foundational papers
| Study | What it tested | Result |
|---|---|---|
| Lu et al. 2020, Nature | OSK reprogramming genes expressed in mouse retinal ganglion cells, in a glaucoma model and in aged mice | Restored youthful DNA methylation patterns, regrew damaged optic-nerve axons after injury, and reversed vision loss |
| Yang et al. 2023, Cell | An inducible system ("ICE") that creates epigenetic disruption without altering the DNA sequence itself, in mice | The induced disruption alone advanced aging at the physiological, cognitive, and molecular level (including the DNA methylation clock) — and OSK reprogramming reversed it |
What actually happened in January 2026
Life Biosciences, a company co-founded by Sinclair, licensed this reprogramming technology from Harvard and tested it in non-human primates before taking it to the FDA. On January 28, 2026, the FDA cleared the company's Investigational New Drug (IND) application for ER-100 — the first partial-epigenetic-reprogramming therapy ever authorized for human testing.
The Phase 1 trial targets two conditions that damage retinal ganglion cells and cause progressive vision loss: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The therapy delivers the same three reprogramming genes used in the 2020 mouse study via a viral vector injected into the eye, with a doxycycline pill used to control how much of the therapy is active — allowing the dose to be adjusted or stopped. Treatment runs about two months per patient.
ER-100 Phase 1 — what it is and isn't
| Question | Answer |
|---|---|
| What is it testing? | Safety and tolerability first (Phase 1) — not yet whether it restores vision in humans |
| Who is eligible? | Patients with open-angle glaucoma or NAION causing vision loss |
| How is it delivered? | Viral vector injected into the eye, with oral doxycycline controlling therapy activity over ~2 months |
| Is it available to the public? | No — this is an enrolling clinical trial, not an approved treatment |
| Does this treat aging generally? | No — it targets eye conditions specifically; there is no reprogramming therapy in human trials for aging itself |
What this means if you're not enrolled in a trial
- There is currently no epigenetic reprogramming product, supplement, or clinic treatment available to consumers with human evidence behind it. Anything marketed under this science today is selling on the mouse data and the trial's existence, not on a demonstrated human result.
- The Phase 1 trial is a safety study in a specific eye disease, run under close medical supervision with a built-in off-switch (doxycycline control) — a very different risk profile from any unsupervised or off-label use of reprogramming factors would be.
- If the trial succeeds on safety, the realistic next step is a larger efficacy trial in the same eye conditions — years away from any broader anti-aging application, if one ever materializes.
- The honest, current takeaway: this is a genuinely serious research program with real mouse data and a real (very early) human trial — worth watching, not worth acting on yet.
Frequently asked questions
Has epigenetic reprogramming reversed aging in humans?
No. The published evidence for reversing aging markers through reprogramming is in mice. A human trial (ER-100, Life Biosciences) began enrolling in 2026 for two eye conditions, but it's a Phase 1 safety study — it has not yet reported whether the therapy works, let alone whether it reverses aging generally.
What is the 'information theory of aging'?
It's David Sinclair's proposal that aging is driven by a progressive loss of epigenetic information — the chemical instructions that tell cells which genes to use — rather than by irreversible damage to DNA itself. The theory predicts that restoring correct epigenetic patterns should reverse aging-related decline, which is what the lab's mouse studies have tested.
Can I get this treatment now?
No. ER-100 is an investigational therapy in an actively enrolling Phase 1 trial for glaucoma and NAION specifically — it is not an approved treatment, and there is no approved or accessible reprogramming therapy for aging in general.
Is this the same as taking NMN, resveratrol, or other longevity supplements?
No. Those are oral compounds sold over the counter with their own (generally much weaker) separate evidence bases. Epigenetic reprogramming is an experimental gene therapy delivered via injection under medical supervision — an entirely different category of intervention, currently confined to a single clinical trial for eye disease.
Keep reading
- Rapamycin for longevity: what the evidence actually shows
Another compound with strong animal data and a real, ongoing gap in human trials.
- Urolithin A for muscle and mitochondria: what the trials actually show
A different mechanism, but the same pattern: real biology, trials that haven't yet delivered on their primary promise.
More in Therapies
- Weight-loss peptides compared: semaglutide, tirzepatide, retatrutide and CagriSema ranked by evidence
Semaglutide, tirzepatide, retatrutide and CagriSema ranked by real trial data — including which ones are actually approved and which are still years away.
- Mounjaro vs Ozempic: which works better, and what it costs you
Tirzepatide beats semaglutide for weight loss in pooled data — but the evidence is weaker than the headlines suggest. Side effects, cost and who each suits.